FDA Approved: RIFABUTIN — Supplemental Application (Mylan Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rifabutin submitted by Mylan Pharmaceuticals Inc. under NDA 050689.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Infection

Drugs mentioned

• RIFABUTIN (Rifabutin)

Snippet

SUPPL AP for RIFABUTIN (RIFABUTIN)